Abstract
This new report puts the generic market in context, providing a review of the
regulatory environment, the major domestic manufacturers, market analysis and
five-year market forecasts to 2012.
The world’s major emerging economies are attracting much investment
and interest. Brazil is not least among them, and it is easy to see why with a
population of 189 million and a GDP of US$978 billion in 2007.
But there are particular attractions for the producers of generic
pharmaceuticals. For years the “generic” market was little more
than a series of copycat products, similar to the branded product but not
necessarily bioequivalent. Under increasing pressure from industry to respect
patents, and with one eye on the need to cost effectively meet the growing
health needs, the Brazilian authorities have led the way in the region in
creating a market for truly bioequivalent generic drugs which now ranks in the
top ten worldwide.
The generics market, already in a strong growth phase, is well placed to
continue its future expansion. The generic production of oral contraceptives
and endogenous hormones was approved in March 2007, a number of leading brands
are due to lose their patent protection over the next 5 years and the use of
generic drugs is expected to grow as price pressures bite.
But who are the leading players and what are their strengths? What barriers to
market entry exist? What routes to market are favourable? What will be the
operating and regulatory environment for companies? The answers to these and
many other questions can be found in this new 200-page management report
Opportunities and Challenges for Bioequivalent Generic Drugs in Brazil
(Published April 2007).
View Cart
